Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...